Journal of Geriatric Cardiology
|
2026, 23(9): 576-589
• RESEARCH ARTICLE •
Sleep-inflammation-coronary plaque phenotype axis: clinical validation and inflammation-mediated mechanisms based on optical coherence tomography
Full
Yang LIU, Xun-Xun FENG, Qian-Yun GUO
✉, Yu-Jie ZHOU
✉
Affiliations
- Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Beijing Institute of Heart Lung and Blood Vessel Disease, Clinical Center for Coronary Heart Disease, Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Published: 2026-09-28
doi: 10.26599/1671-5411.2026.09.002
Outline
Background The influence of sleep duration on vulnerable coronary plaques, as evaluated via optical coherence tomography (OCT), has not been clearly defined in coronary artery disease (CAD). Here, the relationships between habitual sleep duration and thin-cap fibroatheroma (TCFA) detected by OCT were investigated in individuals with CAD. We further investigated whether systemic inflammation, represented by the neutrophil-to-lymphocyte ratio (NLR), represents a mediator of this association.
Methods Overall, 1,178 patients with angiographically confirmed CAD who underwent OCT imaging and completed standardized sleep questionnaires were enrolled. Participants were categorized according to reported sleep duration. Multivariable logistic regression modeling was employed to assess the link between sleep duration and TCFA. Linear regression analyses assessed the association between sleep duration and NLR. Restricted cubic spline (RCS) modeling was applied as a means of detecting possible nonlinear associations between NLR and TCFA. Mediation analyses were then conducted to determine whether NLR functioned as an intermediate variable linking sleep duration and plaque vulnerability.
Results These results offer the first clinical evidence of the link between sleep duration and TCFA presence in individuals with CAD, with the TCFA risk in the abnormal sleep duration group being 2.16 times that of the normal group (95% CI: 1.63-2.88, P < 0.001). Sleep duration was also independently correlated with NLR, and RCS analysis highlighted a nonlinear relationship between NLR levels and TCFA risk (P < 0.001). Importantly, mediation analysis demonstrated that NLR partially mediated the effect of sleep duration on TCFA, supporting the existence of a sleep-inflammation-plaque vulnerability axis.
Conclusion The sleep duration has been shown to be significantly associated with the risk of developing TCFA. In addition, a partial mediating effect of NLR on this relationship has been found.
Yang LIU, Xun-Xun FENG, Qian-Yun GUO, Yu-Jie ZHOU.
Sleep-inflammation-coronary plaque phenotype axis: clinical validation and inflammation-mediated mechanisms based on optical coherence tomography.
老年心脏病杂志（英文）,
2026
, 23
(9)
: 576
-589
.
DOI: 10.26599/1671-5411.2026.09.002
Yang LIU, Xun-Xun FENG, Qian-Yun GUO, Yu-Jie ZHOU.
Sleep-inflammation-coronary plaque phenotype axis: clinical validation and inflammation-mediated mechanisms based on optical coherence tomography[J].
Journal of Geriatric Cardiology,
2026
, 23
(9)
: 576
-589
.
DOI: 10.26599/1671-5411.2026.09.002
- XXF was supported by the grant from China Scholarship Council (CSC) (Grant No. 202308110233). QYG was supported by the grant from Beijing Hospitals Authority Youth Programme (Grant No. QML20210601) and National Natural Science Foundation of China (Grant No. 82300368). YJZ was supported by National Key Research and Development Program of China (Grant No. 2022YFC3602500), Beijing Municipal Administration of Hospitals' Mission plan (Grant No. SML20180601), Capital's Funds for Health Improvement and Research (Grant No. CFH 2020-2-2063), National Natural Science Foundation of China (Grant No. 82070293) and Beijing Municipal Natural Science Foundation (Grant No. 7202041).
[1]
Ford ES, Cunningham TJ, Croft JB. Trends in Self-Reported Sleep Duration among US Adults from 1985 to 2012.
Sleep 2015; 38: 829-832.
[2]
Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023.
J Am Coll Cardiol 2025; 86: 2167-2243.
[3]
Chong B, Jayabaskaran J, Jauhari SM,
et al. Global burden of cardiovascular diseases: projections from 2025 to 2050.
Eur J Prev Cardiol 2025; 32: 1001-1015.
[4]
Nambiema A, Lisan Q, Vaucher J,
et al. Healthy sleep score changes and incident cardiovascular disease in European prospective community-based cohorts.
Eur Heart J 2023; 44: 4968-4978.
[5]
Wang Z, Yang W, Li X,
et al. Association of sleep duration, napping, and sleep patterns with risk of cardiovascular diseases: a nationwide twin study.
J Am Heart Assoc 2022; 11: e025969.
[6]
Lloyd-Jones DM, Allen NB, Anderson CAM,
et al. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association.
Circulation 2022; 146: e18-e43.
[7]
Veler H. Sleep and inflammation: bidirectional relationship.
Sleep Med Clin 2023; 18: 213-218.
[8]
Vergallo R, Park SJ, Stone GW,
et al. Vulnerable or high-risk plaque: a JACC: cardiovascular imaging position statement.
JACC Cardiovasc Imaging 2025; 18: 709-740.
[9]
Li Y, Chen D, Fan Y,
et al. Association between neutrophil to lymphocyte ratio and all-cause mortality in critical patients with coronary artery disease - a study based on the MIMIC-IV database.
Front Cardiovasc Med 2025; 12: 1502964.
[10]
Yang Y, Xu Y, Wang J,
et al. Predictive efficacy of neutrophil-to-lymphocyte ratio for long-term prognosis in new onset acute coronary syndrome: a retrospective cohort study.
BMC Cardiovasc Disord 2020; 20: 500.
[11]
Tian J, Ren X, Vergallo R,
et al. Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study.
J Am Coll Cardiol 2014; 63: 2209-2216.
[12]
Mortensen MB, Dzaye O, Steffensen FH,
et al. Impact of plaque burden versus stenosis on ischemic events in patients with coronary atherosclerosis.
J Am Coll Cardiol 2020; 76: 2803-2813.
[13]
Rao SV, O'Donoghue ML, Ruel M,
et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation 2025; 151: e771-e862.
[14]
Kume T, Okura H, Yamada R,
et al. Frequency and spatial distribution of thin-cap fibroatheroma assessed by 3-vessel intravascular ultrasound and optical coherence tomography: an ex vivo validation and an initial in vivo feasibility study.
Circ J 2009; 73: 1086-1091.
[15]
Garde AH, Hansen ÅM, Holtermann A,
et al. Sleep duration and ischemic heart disease and all-cause mortality: prospective cohort study on effects of tranquilizers/hypnotics and perceived stress.
Scand J Work Environ Health 2013; 39: 550-558.
[16]
Strand LB, Tsai MK, Gunnell D,
et al. Self-reported sleep duration and coronary heart disease mortality: A large cohort study of 400,000 Taiwanese adults.
Int J Cardiol 2016; 207: 246-251.
[17]
Westerlund A, Bellocco R, Sundström J,
et al. Sleep characteristics and cardiovascular events in a large Swedish cohort.
Eur J Epidemiol 2013; 28: 463-473.
[18]
Consensus Conference Panel; Watson NF, Badr MS, Belenky G,
et al. Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society on the Recommended Amount of Sleep for a Healthy Adult: Methodology and Discussion.
J Clin Sleep Med. 2015; 11: 931-952.
[19]
Wang C, Bangdiwala SI, Rangarajan S,
et al. Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries.
Eur Heart J 2019; 40: 1620-1629.
[20]
Ikehara S, Iso H, Date C,
et al. Association of sleep duration with mortality from cardiovascular disease and other causes for Japanese men and women: the JACC study.
Sleep 2009; 32: 295-301.
[21]
Cappuccio FP, Cooper D, D'Elia L,
et al. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies.
Eur Heart J 2011; 32: 1484-1492.
[22]
Van Cauter E, Knutson KL. Sleep and the epidemic of obesity in children and adults.
Eur J Endocrinol 2008; 159(Suppl 1): S59-S66.
[23]
Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite.
Ann Intern Med 2004; 141: 846-850.
[24]
Irwin MR. Sleep and inflammation: partners in sickness and in health.
Nat Rev Immunol 2019; 19: 702-715.
[25]
van Leeuwen WM, Lehto M, Karisola P,
et al. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP.
PLoS One 2009; 4: e4589.
[26]
Faraut B, Boudjeltia KZ, Dyzma M,
et al. Benefits of napping and an extended duration of recovery sleep on alertness and immune cells after acute sleep restriction.
Brain Behav Immun 2011; 25: 16-24.
[27]
Yehuda S, Sredni B, Carasso RL, Kenigsbuch-Sredni D. REM sleep deprivation in rats results in inflammation and interleukin-17 elevation.
J Interferon Cytokine Res 2009; 29: 393-398.
[28]
Calabró P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells.
Circulation 2003; 108: 1930-1932.
[29]
Yan S, Zhang X, Zheng H,
et al. Clematichinenoside inhibits VCAM-1 and ICAM-1 expression in TNF-α-treated endothelial cells via NADPH oxidase-dependent IκB kinase/NF-κB pathway.
Free Radic Biol Med 2015; 78: 190-201.
[30]
Duewell P, Kono H, Rayner KJ,
et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Nature 2010; 464: 1357-1361.
[31]
Hurtado-Alvarado G, Pavón L, Castillo-García SA,
et al. Sleep loss as a factor to induce cellular and molecular inflammatory variations.
Clin Dev Immunol 2013; 2013: 801341.
[32]
Patel SR, Zhu X, Storfer-Isser A,
et al. Sleep duration and biomarkers of inflammation.
Sleep 2009; 32: 200-4.
[33]
Williams CJ, Hu FB, Patel SR, Mantzoros CS. Sleep duration and snoring in relation to biomarkers of cardiovascular disease risk among women with type 2 diabetes.
Diabetes Care 2007; 30: 1233-1240.
[34]
Wang M, Zeng X, Liu Q,
et al. The association between sleep duration and cognitive function in the U. S. elderly from NHANES 2011-2014: A mediation analysis for inflammatory biomarkers.
J Affect Disord 2025; 375: 465-471.
[35]
Prather AA, Vogelzangs N, Penninx BW. Sleep duration, insomnia, and markers of systemic inflammation: results from the Netherlands Study of Depression and Anxiety (NESDA).
J Psychiatr Res 2015; 60: 95-102.
[36]
Grandner MA, Sands-Lincoln MR, Pak VM, Garland SN. Sleep duration, cardiovascular disease, and proinflammatory biomarkers.
Nat Sci Sleep 2013; 5: 93-107.
[37]
Matsubayashi H, Nagai M, Dote K,
et al. Long sleep duration and cardiovascular disease: Associations with arterial stiffness and blood pressure variability.
J Clin Hypertens (Greenwich) 2021; 23: 496-503.
[38]
Grandner MA, Drummond SP. Who are the long sleepers? Towards an understanding of the mortality relationship.
Sleep Med Rev 2007; 11: 341-360.
[39]
Shah AD, Denaxas S, Nicholas O,
et al. Neutrophil Counts and Initial Presentation of 12 Cardiovascular Diseases: A CALIBER Cohort Study.
J Am Coll Cardiol 2017; 69: 1160-1169.
[40]
Fernández-Velasco M, González-Ramos S, Boscá L. Involvement of monocytes/macrophages as key factors in the development and progression of cardiovascular diseases.
Biochem J 2014; 458: 187-93.
[41]
García-Escobar A, Vera-Vera S, Tébar-Márquez D,
et al. Neutrophil-to-lymphocyte ratio an inflammatory biomarker, and prognostic marker in heart failure, cardiovascular disease and chronic inflammatory diseases: New insights for a potential predictor of anti-cytokine therapy responsiveness.
Microvasc Res 2023; 150: 104598.
[42]
Cupido AJ, Kraaijenhof JM, Burgess S,
et al. Genetically Predicted Neutrophil-to-Lymphocyte Ratio and Coronary Artery Disease: Evidence From Mendelian Randomization.
Circ Genom Precis Med 2022; 15: e003553.
[43]
Dong CH, Wang ZM, Chen SY. Neutrophil to lymphocyte ratio predict mortality and major adverse cardiac events in acute coronary syndrome: A systematic review and meta-analysis.
Clin Biochem 2018; 52: 131-136.
[44]
Qin P, Ho FK, Celis-Morales CA, Pell JP. Association between systemic inflammation biomarkers and incident cardiovascular disease in 423,701 individuals: evidence from the UK biobank cohort.
Cardiovasc Diabetol 2025; 24: 162.
[45]
Angkananard T, Anothaisintawee T, McEvoy M,
et al. Neutrophil lymphocyte ratio and cardiovascular disease risk: a systematic review and meta-analysis.
Biomed Res Int 2018; 2018: 2703518.
[46]
Wang Z, Wang J, Cao D, Han L. Correlation of neutrophil-to-lymphocyte ratio with the prognosis of non-ST-segment elevation in patients with acute coronary syndrome undergoing selective percutaneous coronary intervention.
J Int Med Res 2020; 48: 300060520959510.
[47]
Zhou E, Wu J, Zhou X, Yin Y. The neutrophil-lymphocyte ratio predicts all-cause and cardiovascular mortality among U. S. adults with rheumatoid arthritis: results from NHANES 1999-2020.
Front Immunol 2023; 14: 1309835.
[48]
Gu N, Chen P, Wang X,
et al. Association between the neutrophil-to-lymphocyte ratio and in-stent neoatherosclerosis and plaque vulnerability: an optical coherence tomography study.
J Cardiovasc Pharmacol 2024; 84: 506-514.
Year 2026 volume 23 Issue 9
PDF
6
0
Cite this Article
BibTeX
Article Info
doi: 10.26599/1671-5411.2026.09.002
- Online Date：2026-10-30
- Published：2026-09-28
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
